- Home
- PCM vs LONA Comparison
PCM vs LONA Comparison
Compare PCM & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$9.95
Company Overview
Basic Information| Metric | PCM | LONA |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 83.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PCM | LONA |
|---|---|---|
| Price | $5.76 | $9.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 44.8K | ★ 75.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.52 | $4.21 |
| 52 Week High | $6.76 | $14.21 |
Technical Indicators
Market Signals| Indicator | PCM | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 53.87 |
| Support Level | $5.52 | $4.52 |
| Resistance Level | $5.83 | $12.47 |
| Average True Range (ATR) | 0.09 | 1.19 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 70.00 | 24.14 |
Price Performance
Historical Comparison PCM
LONA
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).